These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 22887127

  • 1. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer.
    Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, Kantoff PW.
    Prostate; 2013 Mar; 73(4):346-54. PubMed ID: 22887127
    [Abstract] [Full Text] [Related]

  • 2. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Tinay I, Tan M, Gui B, Werner L, Kibel AS, Jia L.
    Prostate; 2018 Sep; 78(12):927-937. PubMed ID: 29748958
    [Abstract] [Full Text] [Related]

  • 3. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
    Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M.
    PLoS One; 2013 Sep; 8(7):e69239. PubMed ID: 23935962
    [Abstract] [Full Text] [Related]

  • 4. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.
    Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD, Chi KN.
    Int J Mol Sci; 2013 Apr 10; 14(4):7757-70. PubMed ID: 23574937
    [Abstract] [Full Text] [Related]

  • 5. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
    Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L.
    Eur Urol; 2015 Jan 10; 67(1):33-41. PubMed ID: 25129854
    [Abstract] [Full Text] [Related]

  • 6. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease.
    Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, Chi KN, Marshall VR, Tilley WD, Butler LM.
    Int J Cancer; 2012 Aug 01; 131(3):652-61. PubMed ID: 22052531
    [Abstract] [Full Text] [Related]

  • 7. Combining PHI and miRNAs as Biomarkers in Prostate Cancer Diagnosis and Prognosis.
    Ibrahim NH, Abdellateif MS, Thabet G, Kassem SH, El-Salam MA, El-Leithy AA, Selim MM.
    Clin Lab; 2019 Jul 01; 65(7):. PubMed ID: 31307177
    [Abstract] [Full Text] [Related]

  • 8. The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer.
    Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, Brown M, Lee GM, Kantoff PW.
    Prostate; 2012 Jul 01; 72(10):1093-103. PubMed ID: 22127852
    [Abstract] [Full Text] [Related]

  • 9. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer.
    Rönnau CGH, Fussek S, Smit FP, Aalders TW, van Hooij O, Pinto PMC, Burchardt M, Schalken JA, Verhaegh GW.
    World J Urol; 2021 Oct 01; 39(10):3789-3797. PubMed ID: 33990872
    [Abstract] [Full Text] [Related]

  • 10. A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer.
    Daniel R, Wu Q, Williams V, Clark G, Guruli G, Zehner Z.
    Int J Mol Sci; 2017 Jun 16; 18(6):. PubMed ID: 28621736
    [Abstract] [Full Text] [Related]

  • 11. Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies.
    Santos JI, Teixeira AL, Dias F, Maurício J, Lobo F, Morais A, Medeiros R.
    Tumour Biol; 2014 Jul 16; 35(7):7105-13. PubMed ID: 24760272
    [Abstract] [Full Text] [Related]

  • 12. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
    Cheng HH, Plets M, Li H, Higano CS, Tangen CM, Agarwal N, Vogelzang NJ, Hussain M, Thompson IM, Tewari M, Yu EY.
    Prostate; 2018 Feb 16; 78(2):121-127. PubMed ID: 29105802
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Activin A regulates microRNAs and gene expression in LNCaP cells.
    Ottley EC, Nicholson HD, Gold EJ.
    Prostate; 2016 Aug 16; 76(11):951-63. PubMed ID: 27018851
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Global analysis of the differentially expressed miRNAs of prostate cancer in Chinese patients.
    He HC, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, Qin GQ, Cai C, Chen JH, Jiang FN, Liu X, Zhong WD.
    BMC Genomics; 2013 Nov 05; 14():757. PubMed ID: 24191917
    [Abstract] [Full Text] [Related]

  • 18. Circulating microRNAs in plasma before and after radical prostatectomy.
    McDonald AC, Raman JD, Shen J, Liao J, Pandya B, Vira MA.
    Urol Oncol; 2019 Nov 05; 37(11):814.e1-814.e7. PubMed ID: 31421994
    [Abstract] [Full Text] [Related]

  • 19. microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer.
    Zedan AH, Hansen TF, Assenholt J, Pleckaitis M, Madsen JS, Osther PJS.
    Tumour Biol; 2018 May 05; 40(5):1010428318775864. PubMed ID: 29775158
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.